Apremilast

Apremilast is an oral PDE4 inhibitor used in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. It modulates inflammatory mediators to reduce symptoms. Mediocon Inc supplies pharmaceutical-grade Apremilast meeting IP/BP/EP/USP standards for pharma manufacturers.

Key Features

• Oral PDE4 inhibitor
• IP/BP/EP/USP compliant quality
• Psoriasis and psoriatic arthritis treatment
• Suitable for oral tablet formulations

Applications

• Oral tablets for plaque psoriasis
• Psoriatic arthritis therapy
• Immunomodulatory drug manufacturing
• Pharmaceutical research

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings